Blueprint Medicines Corp
BPMC98.175USD
+8.675+9.69%
交易中 （美东）报价延迟15分钟
6.25B总市值
亏损市盈率 TTM
关于 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精准治疗公司，正在过敏/炎症和肿瘤/血液学两个领域发明改变生命的药物。该公司向美国和欧洲的患者提供其获批的药物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，并在全球范围内推进针对系统性肥大细胞增多症 (SM)、肺癌、乳腺癌和其他基因组定义的癌症以及癌症免疫疗法的多个项目。该公司的产品线还包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究项目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外显子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。该公司正在开发一种口服、有效且高选择性的试验性 KIT 抑制剂 Elenestinib (BLU-263)，用于治疗惰性 SM 和其他肥大细胞疾病。
公司简介
公司代码BPMC
公司名称Blueprint Medicines Corp
上市日期Apr 30, 2015
成立日期2008
CEOMs. Kathryn D (Kate) Haviland
员工数量649
证券类型Ordinary Share
年结日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02139
电话16173747580
网址https://www.blueprintmedicines.com/
公司代码BPMC
上市日期Apr 30, 2015
成立日期2008
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Dr. Christopher K. Murray, Ph.D.
Dr. Christopher K. Murray, Ph.D.
Executive Vice President, Chief Technical Operations and Quality Officer
Executive Vice President, Chief Technical Operations and Quality Officer
28.60K
+48.63%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
23.94K
-13.94%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.09K
+56.18%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
+19.95%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024Q3
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
地区USD
名称
营收
占比
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
业务
地区
业务USD
名称
营收
占比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
股东统计
更新时间: 2月23日 周日
更新时间: 2月23日 周日
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
49.33%
Investment Advisor
40.93%
Hedge Fund
10.05%
Research Firm
2.72%
Sovereign Wealth Fund
1.10%
Individual Investor
1.08%
Venture Capital
1.04%
Pension Fund
0.55%
Bank and Trust
0.45%
机构持股
更新时间: 2月24日 周一
更新时间: 2月24日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
658
69.72M
107.98%
-1.29M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.69M
2.64%
-1.98M
-53.96%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
Macquarie Investment Management
1.26M
1.97%
-4.68K
-0.37%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Invesco Biotechnology & Genome ETF
2.8%
WisdomTree BioRevolution Fund
2.56%
Tema Oncology ETF
2.52%
Range Cancer Immunotherapy ETF
1.97%
SPDR S&P Biotech ETF
1.82%
Virtus LifeSci Biotech Products ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
American Century Focused Dynamic Growth ETF
1.02%
iShares Health Innovation Active ETF
0.88%
JPMorgan Fundamental Data Science Small Core ETF
0.88%
查看更多
Invesco Biotechnology & Genome ETF
占比2.8%
WisdomTree BioRevolution Fund
占比2.56%
Tema Oncology ETF
占比2.52%
Range Cancer Immunotherapy ETF
占比1.97%
SPDR S&P Biotech ETF
占比1.82%
Virtus LifeSci Biotech Products ETF
占比1.68%
Direxion Daily S&P Biotech Bull 3X Shares
占比1.16%
American Century Focused Dynamic Growth ETF
占比1.02%
iShares Health Innovation Active ETF
占比0.88%
JPMorgan Fundamental Data Science Small Core ETF
占比0.88%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据